The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,810.00
Bid: 1,807.50
Ask: 1,808.50
Change: 10.50 (0.58%)
Spread: 1.00 (0.055%)
Open: 1,797.00
High: 1,810.00
Low: 1,792.00
Prev. Close: 1,799.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Investors Warm To Centrica Results

Thu, 18th Feb 2016 10:34

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.
----------
FTSE 100 - WINNERS
----------
Centrica, up 3.7%. The gas distributor and producer reported full-year results that significantly beat expectations, as the drag on earnings from its upstream unit was not as bad as expected. Centrica reported a 4% fall in net earnings to GBP863.0 million in 2015 from GBP903.0 million in 2014, but the figure was significantly higher than analyst expectations of GBP733.0 million. Adjusted operating cashflow, which Centrica said would be a "major focus" back in December, came in ahead of Centrica's guidance at GBP2.25 billion, which was also up 2% from GBP2.20 billion last year. Revenue for 2015 fell 5% to GBP28.00 billion. The dividend for the year will be 12.0 pence per share, down from 13.5 pence in 2014.

BAE Systems, up 1.3%. The defence contractor said recovering global defence budgets should result in higher earnings in 2016, even though pretax profit was given a one-off boost in 2015 by aircraft deliveries to Saudi Arabia. Pretax profit rose to GBP1.09 billion in 2015 from GBP882.0 million in 2014, helped by a rise in revenue to GBP17.90 billion from GBP16.64 billion and lower impairment and amortisation charges. BAE said it will pay a final dividend of 12.5 pence per share, taking its total dividend to 20.9p, up 2.0% year-on-year from the 20.5p it paid in 2014.
----------
FTSE 100 - LOSERS
----------
Royal Dutch Shell 'A' shares, down 2.5%, 'B' shares, down 2.2%, GlaxoSmithKline, down 0.6%, and AstraZeneca, down 1.3%. The stocks went ex-dividend meaning new buyers no longer qualify for dividend payouts.

Hammerson, down 1.2%. The property developer was downgraded to Neutral from Overweight by JPMorgan.
----------
FTSE 250 - WINNERS
----------
Go-Ahead Group, up 5.0%. The transport company said its first-half results met its expectations and affirmed its outlook for the full year as it saw solid performances in its bus and rail divisions. Pretax profit for the half-year to December 26 was GBP52.1 million, up from GBP44.7 million a year earlier, helped by a big rise in profit from its rail division. Go-Ahead will pay an interim dividend of 28.33 pence per share, up from 26.60p a year earlier. Shore Capital upgraded the stock to Buy from Hold. The broker noted the company's shares have fallen by 16% year-to-date, giving them an attractive set of multiple and yield metrics.

Indivior up 2.6%. The pharmaceutical group said pretax profit about halved in 2015 as it was hit by a lower average market share and higher rebates in the US, leaving it expecting a fall in revenue in 2016. Indivior said its pretax profit for the year to the end of December was USD285.0 million, down from USD561.0 million a year earlier. Net revenue fell to USD1.01 billion in 2015 from USD1.12 billion in 2014, down 9.0%, and the profit line was hit further by higher operating costs for Indivior as a standalone company, having been spun-out of consumer goods giant Reckitt Benckiser in 2014. Indivior will pay a final dividend of 9.5 cents per share, taking its total dividend to 12.7 cents.
----------
FTSE 250 - LOSERS
----------
Tullow Oil, down 5.6%. The oil and gas company said it has implemented extra "operational procedures" on the floating production, storage and offloading vessel serving the Jubilee field offshore Ghana after identifying an potential issue in the turret area. Tullow said an inspection of the turret area of the FPSO was carried out by SOFEC, the original manufacturer of the turret, which identified "a potential issue" with the turret bearing.

PZ Cussons, down 1.2%. The soaps and toiletries maker's stock went ex-dividend.
----------
MAIN MARKET AND AIM - WINNERS
----------
Amerisur Resources, up 17%. The oil and gas company said its shareholders are set to benefit "tremendously" from its pipeline project which ultimately aims to connect the Platanillo field in Colombia with the oil pipeline system in Ecuador, named Oleoducto Binacional Amerisur. Amerisur said it has secured all the necessary approvals to begin drilling and installing a pipeline under a river as part of the project to connect the Colombian oilfield with the oil pipeline system in Ecuador.

Providence Resources, up 16%. The oil and gas company said it is continuing discussions with potential partners on the Barryroe oilfield offshore Ireland and contemplating how to best conduct future drilling operations on the site. Providence holds an 80% stake and operates the offshore field, with fellow London-listed firm Lansdowne Oil & Gas holding the other 20%. Providence said it is still holding talks with third parties about bringing in another partner to the asset, and said it is also considering a proposal from an alliance of its contractors about implementing a "risk-sharing model" to the future drilling programme. Lansdowne Oil shares were up 15%.

Victoria Oil & Gas, up 12%. The oil and gas company said it has expanded its operations in Cameroon after it purchased a 75% stake in the Matanda licence from a subsidiary of commodity giant Glencore. Glencore Exploration Cameroon has agreed to sell its 75% stake in the production sharing contract covering the 1,235 square kilometre Matanda block to Victoria Oil for an undisclosed amount. Glencore shares were down 0.6%.
----------
MAIN MARKET AND AIM - LOSERS
----------
North Midland Construction, down 4.6%. The civil engineering and building contractor said profit for the year will be significantly below its expectations after the resolution of legacy contracts proved weaker than expected. The company said it has now concluded the resolution of a series of legacy contracts, with only one left to conclude, but the settlement figures it had expected have not been achieved, resulting in total additional losses of GBP3.1 million. Solid trading means the group expects to post a profit for 2015, but this will be significantly below its previous expectations.
----------
By Arvind Bhunjun; arvindbhunjun@alliancenews.com; @ArvindBhunjun

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
25 Sep 2023 07:28

GSK's RSV vaccine gets approval in Japan

(Sharecast News) - GSK announced on Monday that its vaccine, Arexvy, has received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for preventing respiratory syncytial virus (RSV) disease in adults aged 60 and over.

Read more
19 Sep 2023 09:30

GSK says new HIV PrEP medication authorised by European Commission

(Alliance News) - GSK PLC on Tuesday said the European Commission has authorised ViiV Healthcare's "superior" drug Apretude to reduce the risk of sexually acquired HIV-1 infection.

Read more
18 Sep 2023 09:40

LONDON BROKER RATINGS: Jefferies likes Energean; JPMorgan raises IDS

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
18 Sep 2023 07:57

LONDON BRIEFING: Phoenix Group hails "impressive" first-half

(Alliance News) - Stocks in London are called lower on Monday, as investors focus on the week's upcoming central bank decisions.

Read more
18 Sep 2023 07:18

US FDA approves GSK treatment for myelofibrosis

(Sharecast News) - GSK announced on Monday that the US Food and Drug Administration (FDA) has granted approval for 'Ojjaara', or momelotinib, as a treatment for adults suffering from intermediate or high-risk myelofibrosis with anaemia, including cases of primary myelofibrosis or secondary myelofibrosis.

Read more
15 Sep 2023 21:52

GSK's Ojjaara approved in US for myelofibrosis patients with anaemia

(Alliance News) - GSK PLC on Friday said Ojjaara, also known as momelotinib, has been approved in the US and the "first and only" treatment indicated for myelofibrosis patients with anaemia.

Read more
11 Sep 2023 08:24

Japan accepts GSK's regulatory filing for momelotinib for blood cancer

(Alliance News) - GSK PLC on Monday reported regulatory progress for momelotinib, as Japan's Ministry of Health, Labour & Welfare accepted a review for the blood cancer-focused drug.

Read more
11 Sep 2023 07:54

LONDON BRIEFING: Restaurant Group sells Frankie & Benny's and Chiquito

(Alliance News) - Stocks in London are called higher on Monday, ahead of a busy week of interest rate decisions and economic data.

Read more
6 Sep 2023 09:32

LONDON BROKER RATINGS: Shore says 'buy' B&M; Peel Hunt likes Halfords

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning:

Read more
4 Sep 2023 06:00

More UK babies to need hospital treatment over delay of GSK's RSV jab

(Alliance News) - The nation's top children's doctor has warned a delay on a new vaccine to combat respiratory syncytial virus, or RSV, will mean more babies and infants will need hospital treatment this winter.

Read more
1 Sep 2023 09:11

GSK antibody accepted for Japan review, Goldman Sachs reduces stake

(Alliance News) - GSK PLC on Friday said a new drug application for its monoclonal antibody mepolizumab has been accepted for review by the Japanese government.

Read more
1 Sep 2023 07:49

LONDON BRIEFING: Stocks seen higher; UK house prices continue to fall

(Alliance News) - Stocks in London are set to open higher on Friday as markets looked ahead to a data-heavy day.

Read more
1 Sep 2023 07:12

Japan considering GSK's Nucala drug for sinusitis treatment

(Sharecast News) - Japanese regulators are reviewing a new drug application for GSK's Nucala treatment to be used for the treatment of form of adult sinusitis, the biopharma giant announced on Friday.

Read more
23 Aug 2023 12:10

LONDON MARKET MIDDAY: Stocks rise but pound slumps on sub-par UK data

(Alliance News) - Stocks in Europe were on the up heading into Wednesday afternoon, with equity markets in a confident mood on the eve of the Jackson Hole central banking event, shaking off tepid economic data which hurt the pound and euro.

Read more
23 Aug 2023 08:17

GSK gets positive results from shingles trial of Shingrix in China

(Alliance News) - GSK PLC on Wednesday celebrated positive results from the first-ever efficacy trial of its preventative shingles treatment, Shingrix, in China.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.